Switch View
© BusinessWire
25.08.2025
ISIN: US45337C1027
Incyte Corp
INCY
LISTED
NASDAQ
Incyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer
News Preview
Incyte (Nasdaq:INCY) announces that Soni Basi has been appointed Executive Vice President and Chief Human Resources Officer (CHRO) effective today, August 25, 2025. In her new role, Ms. Basi will serve as a key member of the Executive Leadership Team and be responsible for shaping the Company’s global human resources strategy including talent acqu...
Themefolio
Profiler
Peergroup
© BusinessWire
25.08.2025
ISIN: US30052C1071
Evolus Inc
EOLS
LISTED
NASDAQ
Evolus Announces Positive Data From Pivotal Trial for Evolysse™ Sculpt Injectable Hyaluronic Acid Gel Product at 2025 Cosmetic Bootcamp
News Preview
Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced positive topline results from a U.S. pivotal study of Evolysse™ Sculpt, an injectable hyaluronic acid (HA) gel product designed to restore mid-face volume.
“Achieving positive topline results in our mid-fa...
Themefolio
Profiler
Peergroup
© BusinessWire
25.08.2025
ISIN: US6323071042
Natera Inc
NTRA
LISTED
NASDAQ
Natera to Present Signatera™ Data at the IASLC World Conference on Lung Cancer
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced that it will present new data at the 2025 International Association for the Study of Lung Cancer (IASLC) World Conference on Lung Cancer, taking place September 6 - 9 in Barcelona, Spain. The presentations underscore the strong clinical utility of...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Leerverkaufsstatistiken, Hedge-Fund Aktivitäten und viele weitere nutzerwertige Informationen benutzerfreundlich aufbereitet
© BusinessWire
25.08.2025
ISIN: US4448591028
Humana Inc
HUM
LISTED
NYSE
Humana Earns 2025 Great Place to Work Certification™ and PEOPLE Companies That Care® Recognition
News Preview
Humana Inc. (NYSE: HUM), one of the nation’s leading health and well-being companies, has been named a Certified™ Great Place To Work® for the fourth consecutive year and has earned a place on PEOPLE® Companies that Care list for the second year in a row. Both honors are based on direct employee feedback and recognize organizations that prioritize...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
20.10.2025
© PR Newswire
25.08.2025
ISIN: US68236V3024
ETHZilla Corporation
ETHZ
LISTED
NASDAQ
ETHZilla announces authorization of $250 million stock repurchase program
News Preview
Company has accumulated 102,237 ETH at an average acquisition price of $3,948.72, which is now valued at approximately $489 million
Announces implementation of proprietary Electric Asset Protocol to generate higher yields
PALM BEACH, Fla., Aug. 25, 2025 /PRNewswire/ -- ETHZilla Corporation (Nasdaq: ETHZ), (the "Company" or "ETHZilla"), today anno...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
ISIN: US45258H1068
Immix Biopharma, Inc.
IMMX
LISTED
NASDAQ
Immix Biopharma to Present at the Stifel 2025 Healthcare Conference
News Preview
Los Angeles, CA, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it will present and host institutional investor meetings at the Stifel 2025 Healthcare Co...
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
ISIN: IL0011313900
Galmed Pharmaceuticals Ltd.
GLMD
LISTED
NASDAQ
Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value
News Preview
An amendment to the Company's Articles of Association to increase the authorized share capital from 50,000,000 ordinary shares to 900,000,000 ordinary shares was approved at the Company's Special General Meeting of shareholders held on August 15, 2025The Company is initially planning to invest up to $10M representing approximately 50% of its curr...
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
ISIN: US98956P1021
Zimmer Biomet Holdings Inc
ZBH
LISTED
NYSE
Zimmer Biomet to Present at the Annual Morgan Stanley Healthcare Conference
News Preview
WARSAW, Ind., Aug. 25, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced that members of the Zimmer Biomet management team will be presenting at the Annual Morgan Stanley Healthcare Conference on Monday, September 8, 2025, at 8:30 a.m. ET....
Themefolio
Profiler
Peergroup
© BusinessWire
25.08.2025
ISIN: US68218J1034
OmniAb Inc
OABI
LISTED
NASDAQ
OmniAb Announces $30 Million Private Placement
News Preview
OmniAb, Inc. (NASDAQ: OABI) today announced it has entered into a definitive securities purchase agreement to issue and sell an aggregate of 21,254,106 shares of its common stock at a price of $1.40 per share (or $1.85 per share for officer and director participation), in a private placement. OmniAb anticipates the gross proceeds from the private...
Themefolio
Profiler
Peergroup
© BusinessWire
25.08.2025
ISIN: US86150R1077
Stoke Therapeutics Inc
STOK
LISTED
NASDAQ
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
News Preview
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body’s potential with RNA medicine, and Biogen Inc. (Nasdaq: BIIB), today announced presentations of new clinical data from studies of zorevunersen at the 36th International Epilepsy Congress (IEC), taking place August 30 –...
Themefolio
Profiler
Peergroup
© BusinessWire
25.08.2025
ISIN: US98422E1038
Xeris Biopharma Holdings Inc
XERS
LISTED
NASDAQ
Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®
News Preview
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced the U.S Patent and Trademark Office has issued patent number 12,377,096 to the Company for Recorlev® (levoketoconazole) and t...
Themefolio
Profiler
Peergroup
© BusinessWire
25.08.2025
ISIN: JE00BYSS4X48
Novocure Ltd
NVCR
LISTED
NASDAQ
Novocure Announces Coverage of Tumor Treating Fields (TTFields) Therapy for Patients with Newly Diagnosed Glioblastoma in Spain
News Preview
Novocure (NASDAQ: NVCR) announced today that Spain’s Ministry of Health has made Tumor Treating Fields (TTFields) therapy available through the Spanish National Health System (SNS) for the treatment of adult patients with newly diagnosed glioblastoma.
“Glioblastoma is one of the most common and aggressive forms of primary brain cancer with few t...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
25.08.2025
ISIN: US64051A1016
NeOnc Technologies Holdings Inc
NTHI
LISTED
NASDAQ
NeOnc Technologies Closes Strategic Acquisition of Advanced AI and 3D Bioprinting IP, Appointing World-Renowned Scientist Dr. Ishwar K. Puri to its Board
News Preview
CALABASAS, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ:NTHI), a multi-Phase 2 clinical-stage biotechnology company pioneering therapies for central nervous system (CNS) cancers, today announced the closing of its acquisition of an intellectual property portfolio featuring artificial intelligence, 3D bioprin...
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
ISIN: IE00B56GVS15
Alkermes Plc
ALKS
LISTED
NASDAQ
Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025
News Preview
– Results From Vibrance-1 to Be Shared in Three Oral Presentations, Including Primary and Secondary Efficacy and Safety Measures, and Exploratory Patient-Reported Outcomes Related to Disease Severity, Fatigue and Cognition –
– Company to Host Investor Webcast on Monday, Sept. 8 at 8:00 a.m. ET –
DUBLIN, Aug. 25, 2025 /PRNewswire/ -- Alkermes pl...
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
ISIN: CA50190N1042
LSL Pharma Group Inc.
LSL
LISTED
TSX
LSL PHARMA GROUP REPORTS THIRD CONSECUTIVE RECORD QUARTERLY REVENUES AND Q2 2025 FINANCIAL RESULTS
News Preview
Expanded Eye-Care portfolio by signing two agreements to market up to 16 sterile eye drops in CanadaEntered into a non-binding letter of intent to acquire a Quebec-based CMOFiled supplemental information to the FDA to qualify Steri-Med for manufacturing ointment products for the US marketSecured $17.5 million bank financingRedeemed $3.3 million...
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
ISIN: IE00B56GVS15
Alkermes Plc
ALKS
LISTED
NASDAQ
Alkermes to Present Detailed Positive Results From Vibrance-1 Phase 2 Study Evaluating Alixorexton in Patients With Narcolepsy Type 1 at World Sleep 2025
News Preview
– Results From Vibrance-1 to Be Shared in Three Oral Presentations, Including Primary and Secondary Efficacy and Safety Measures, and Exploratory Patient-Reported Outcomes Related to Disease Severity, Fatigue and Cognition –
– Company to Host Investor Webcast on Monday, Sept. 8 at 8:00 a.m. ET –
DUBLIN, Aug. 25, 2025 /PRNewswire/ -- Alkermes pl...
Themefolio
Profiler
Peergroup
© BusinessWire
25.08.2025
ISIN: US1101221083
Bristol-Myers Squibb Co
BMY
LISTED
NYSE
Bristol Myers Squibb to Present New Clinical and Real-World Data at the European Society of Cardiology Congress 2025
News Preview
Bristol Myers Squibb (NYSE: BMY) today announced the presentation of new clinical and real-world data from its cardiovascular portfolio at the European Society of Cardiology (ESC) Congress, taking place August 29 – September 1, 2025, in Madrid, Spain. Data to be presented at the meeting include new real-world analyses of Camzyos (mavacamten) in pa...
Themefolio
Profiler
Peergroup
© BusinessWire
25.08.2025
ISIN: US58933Y1055
Merck & Co Inc
MRK
LISTED
NYSE
Merck Demonstrates Ongoing Commitment to Advancing Cardiovascular Disease Management and Patient Care with New Data at the European Society of Cardiology Congress 2025
News Preview
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced that new clinical trial and outcomes research data will be presented at the European Society of Cardiology Congress (ESC) 2025 in Madrid, Spain from August 29 – September 1. Data presented at ESC include Merck’s latest research focusing on atherosclerotic cardiovasc...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
ISIN: US70465T1079
PDS Biotechnology Corp
PDSB
LISTED
NASDAQ
PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer
News Preview
Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of care pembrolizumab or pembrolizumab + chemotherapy is 17.9 months*...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
ISIN: US14888U1016
Catalyst Pharmaceuticals Inc
CPRX
LISTED
NASDAQ
Catalyst Pharmaceuticals Announces Settlement of FIRDAPSE® (amifampridine) Patent Litigation with Lupin Pharmaceuticals
News Preview
As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035 As Part of the Settlement, Lupin Receives a License to Market Generic FIRDAPSE Beginning in February 2035...
Themefolio
Profiler
Peergroup
© BusinessWire
25.08.2025
ISIN: US07725L1026
BeOne Medicines Ltd.
ONC
LISTED
NASDAQ
BeOne Medicines Announces IMDELLTRA Royalty Purchase Agreement for up to $950 Million
News Preview
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced it has entered into an agreement to sell its royalty rights on the worldwide sales, excluding China, of Amgen’s IMDELLTRA® (tarlatamab-dlle) for up to $950 million to Royalty Pharma (Nasdaq: RPRX).
Under the terms of the agreement, BeOne will...
Themefolio
Profiler
Peergroup
© Newsfile
25.08.2025
ISIN: CA41138T1057
Happy Belly Food Group Inc.
HBFG
LISTED
CSE
Happy Belly Food Group's Heal Wellness Signs Real-Estate Location with Muli-Unit Franchisee at Victoria's University Heights
News Preview
Toronto, Ontario--(Newsfile Corp. - August 25, 2025) - Happy Belly Food Group Inc. (CSE: HBFG) (OTCQB: HBFGF) ("Happy Belly" or the "Company"), a leader in acquiring and scaling emerging food brands across Canada is pleased to announce that further to its signed Multi-Unit Franchise Agreement for 5 Stores on Vancouver Island, British Columbia on Ju...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
ISIN: ES0167733015
Oryzon Genomics SA
ORY
LISTED
BME
ORYZON Receives European Medicines Agency Approval to Initiate a Phase Ib Study of Iadademstat in Sickle Cell Disease
News Preview
MADRID and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, Ticker: ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, today announced that the European Medicines Agency (EMA) has approved its Clinical Trial Application (CTA), the European equivalent to an IND,...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
ISIN: US35104E1001
4D Molecular Therapeutics Inc
FDMT
LISTED
NASDAQ
4DMT to Participate in Upcoming Investor Conferences
News Preview
EMERYVILLE, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that management will par...
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
ISIN: KYG8807B1068
Theravance Biopharma Inc
TBPH
LISTED
NASDAQ
Theravance Biopharma Completes Enrollment in Pivotal Phase 3 CYPRESS Study of Ampreloxetine in Patients with Symptomatic Neurogenic Orthostatic Hypotension due to Multiple System Atrophy
News Preview
Topline results anticipated in Q1 2026 and, if successful, planning for expedited NDA submission If approved, ampreloxetine could address a critical unmet need as the first therapy with the potential to provide durable benefit for the 40,000 patients in the U.S. with symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple s...
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
ISIN: US45166A1025
IDEAYA Biosciences Inc
IDYA
LISTED
NASDAQ
IDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations Events
News Preview
SOUTH SAN FRANCISCO, Calif., Aug. 25, 2025 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in the upcoming investor relations events....
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
ISIN: US8106481059
scPharmaceuticals, Inc.
SCPH
LISTED
NASDAQ
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
News Preview
DANBURY, Conn. and BURLINGTON, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD) and scPharmaceuticals Inc. (Nasdaq: SCPH) today announced the signing of a definitive merger agreement for MannKind to acquire scPharmaceuticals....
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
ISIN: CA10778Y1043
BriaCell Therapeutics Corp.
BCT
LISTED
TSX
BriaCell Awarded $2 Million NCI Grant to Advance Bria-PROS+™ in Prostate Cancer
News Preview
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 25, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ), (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce that the National Cancer Institute (NCI), th...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
ISIN: US23282W6057
Cytokinetics Inc
CYTK
LISTED
NASDAQ
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology Congress 2025
News Preview
Positive Results from MAPLE-HCM to be Shared in Hot Line Presentation...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
ISIN: US10806X1028
BridgeBio Pharma, Inc.
BBIO
LISTED
NASDAQ
BridgeBio to Present Additional Open-label Extension Data from ATTRibute-CM at ESC Congress 2025
News Preview
PALO ALTO, Calif., Aug. 25, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, announced today that one rapid-fire oral presentation on additional open-label extension data from ATTRibute-CM and two ePosters with ATTRibute-CM data at M...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
ISIN: US74346N4043
Propanc Biopharma, Inc.
PPCB
LISTED
OTC
Propanc Biopharma Provides Shareholder Update
News Preview
Propanc is entering a transformational stage as it prepares for the advancement of its lead asset, “PRP”, to enter a Phase 1B, First-In-Human (FIH) study...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
ISIN: US56400P2011
MannKind Corporation
MNKD
LISTED
NASDAQ
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases
News Preview
MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
ISIN: US0080642061
Jade Biosciences Inc
JBIO
LISTED
NASDAQ
Jade Biosciences to Participate in Upcoming Conferences
News Preview
Jade Biosciences to Participate in Upcoming Conferences...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
ISIN: US8294011080
Sionna Therapeutics Inc
SION
LISTED
NASDAQ
Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis
News Preview
Dosing initiated for SION-451 combined with SION-2222 and SION-451 combined with SION-109 in healthy volunteers; topline data anticipated in mid-2026 Dosing initiated for SION-451 combined with SION-2222 and SION-451 combined with SION-109 in healthy volunteers; topline data anticipated in mid-2026...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
ISIN: US09062X1037
Biogen Inc
BIIB
LISTED
NASDAQ
Biogen and Stoke Therapeutics Announce Presentations of Clinical Data from Studies of Zorevunersen for the Potential Treatment of Dravet Syndrome at the 36th International Epilepsy Congress
News Preview
– 3-year data from open-label extension (OLE) studies demonstrate the potential for disease modification with durable seizure reductions and improvements in cognition and behavior on top of standard anti-seizure medicines –...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
ISIN: US14843C1053
Castle Biosciences Inc
CSTL
LISTED
NASDAQ
New Evidence Published Supporting Use of DecisionDx®-SCC Test in Guiding and Improving Treatment Pathway Decisions in NCCN High-Risk Cutaneous Squamous Cell Carcinoma
News Preview
Castle announced the publication of two new studies related to its DecisionDx-SCC test for patients with high-risk cutaneous squamous cell carcinoma....
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
ISIN: US07373V1052
Beam Therapeutics Inc
BEAM
LISTED
NASDAQ
Beam Therapeutics to Participate in Upcoming September 2025 Investor Conferences
News Preview
Beam Therapeutics Inc. (Nasdaq: BEAM) management will be participating in several healthcare investor conferences in September...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
ISIN: US05463X1063
AxoGen Inc
AXGN
LISTED
NASDAQ
Axogen Provides Update on FDA Review Timeline for Avance Nerve Graft
News Preview
FDA PDUFA goal date extended by three months FDA PDUFA goal date extended by three months...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
ISIN: GB00BMVP7Y09
Royalty Pharma PLC
RPRX
LISTED
NASDAQ
Royalty Pharma to Acquire Royalty Interest in Amgen’s Imdelltra for up to $950 Million
News Preview
NEW YORK, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in Amgen’s Imdelltra, a first-in-class DLL3 targeting bispecific T-cell engager (BiTE), from BeOne Medicines for $885 million upfront. The agreement includes an option for BeOne to sell additional Imdelltra royalti...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
25.08.2025
ISIN: US0050831009
Actuate Therapeutics, Inc.
ACTU
LISTED
NASDAQ
Actuate Therapeutics Advances a New Era in Oncology with Potential Universal Backbone Therapy
News Preview
Phase 2 study showed a doubling of the survival rate of metastatic pancreatic cancer patients at Year 1, an unprecedented outcomeTechnology is seen as transformative in increasing the effectiveness of treatment for a wide range of cancers CHICAGO, IL AND FORT WORTH, TX / ACCESS Newswire / August 25, 2025 / Vexing challenges await cancer researchers...
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
ISIN: DK0061804697
H Lundbeck A/S
HLUN A
LISTED
CPH
Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy
News Preview
The full results of the open label extension (OLE) of the Phase 1b/2a PACIFIC trial investigating bexicaserin for the treatment of patients with Developmental and Epileptic Encephalopathies (DEEs), will be presented for the first time at the International Epilepsy Annual Congress1DEEs are the most severe rare epilepsies, characterized by drug-res...
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
ISIN: DK0061804697
H Lundbeck A/S
HLUN A
LISTED
CPH
Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy
News Preview
The full results of the open label extension (OLE) of the Phase 1b/2a PACIFIC trial investigating bexicaserin for the treatment of patients with Developmental and Epileptic Encephalopathies (DEEs), will be presented for the first time at the International Epilepsy Annual Congress1DEEs are the most severe rare epilepsies, characterized by drug-res...
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
ISIN: SE0010323311
BioArctic AB
BIOA B
LISTED
STO
Leqembi® (lecanemab) launched in the EU today
News Preview
STOCKHOLM, Aug. 25, 2025 /PRNewswire/ --BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the launch of Leqembi in the EU started in Austria on August 25, 2025, and will be launched in Germany on September 1, 2025. Leqembi received the European Commission (EC) approval in April 2025 as the first therapy that targ...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
25.08.2025
ISIN: US5845073056
Medical Care Technologies Inc.
MDCE
LISTED
OTC
$12.9M Dual Logoman Auto Sale Highlights MDCE (OTC PINK:MDCE) Subsidiary Infinite Auctions' Move Into Tom Brady 1/1 NFL Logo Auto
News Preview
Acquisition underscores Infinite Auctions' momentum as 1-of-1 cards of sports legends reach record-breaking values MESA, ARIZONA / ACCESS Newswire / August 25, 2025 / Medical Care Technologies Inc. (OTC PINK:MDCE) today announced that its subsidiary, Infinite Auctions, has successfully acquired a Tom Brady 2009 Topps Unique Game-Worn NFL Logo Shiel...
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
ISIN: DK0061804697
H Lundbeck A/S
HLUN A
LISTED
CPH
Lundbeck to present new data on bexicaserin at upcoming congress, highlighting long-term impact on seizure frequency in patients with rare epilepsy
News Preview
The full results of the open label extension (OLE) of the Phase 1b/2a PACIFIC trial investigating bexicaserin for the treatment of patients with Developmental and Epileptic Encephalopathies (DEEs), will be presented for the first time at the International Epilepsy Annual Congress1DEEs are the most severe rare epilepsies, characterized by drug-res...
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
ISIN: SE0010323311
BioArctic AB
BIOA B
LISTED
STO
Leqembi® (lecanemab) launched in the EU today
News Preview
STOCKHOLM, Aug. 25, 2025 /PRNewswire/ --BioArctic AB's (publ) (NASDAQ Stockholm: BIOA B) partner Eisai announced today that the launch of Leqembi in the EU started in Austria on August 25, 2025, and will be launched in Germany on September 1, 2025. Leqembi received the European Commission (EC) approval in April 2025 as the first therapy that targ...
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
ISIN: AU000000TLX2
Telix Pharmaceuticals Ltd
TLX
LISTED
ASX
TLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law Firm
News Preview
LOS ANGELES, Aug. 25, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Telix Pharmaceuticals Limited ("Telix" or "the Company") (NASDAQ: TLX) for violations of the securities laws....
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
ISIN: US4330001060
Hims & Hers Health Inc
HIMS
LISTED
NYSE
HIMS Investors Have Opportunity to Lead Hims & Hers Health, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Aug. 25, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Hims & Hers Health, Inc. ("Hims & Hers" or "the Company") (NYSE: HIMS) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated ther...
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
ISIN: US8036071004
Sarepta Therapeutics Inc
SRPT
LISTED
NASDAQ
SRPT Shareholders Have the Right to Lead the Sarepta Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group Before the Final Deadline - SRPT
News Preview
LOS ANGELES, Aug. 25, 2025 /PRNewswire/ -- The DJS Law Group reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of the federal securities laws.
Shareholders who purchased the Company's securities between June 22, 2023 and June 24, 2025, inclusive (the "Class P...
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
ISIN: US8036071004
Sarepta Therapeutics Inc
SRPT
LISTED
NASDAQ
SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm
News Preview
LOS ANGELES, Aug. 25, 2025 /PRNewswire/ -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Sarepta Therapeutics, Inc. ("Sarepta" or "the Company") (NASDAQ: SRPT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder b...
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
ISIN: US4330001060
Hims & Hers Health Inc
HIMS
LISTED
NYSE
Hims & Hers Health, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - HIMS
News Preview
LOS ANGELES, Aug. 25, 2025 /PRNewswire/ -- The DJS Law Group announces that it is investigating claims on behalf of investors of Hims & Hers Health, Inc. ("Hims & Hers" or "the Company") (NYSE: HIMS) for violations of the securities laws.
INVESTIGATION DETAILS: The investigation focuses on whether the Company issued misleading statements...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
25.08.2025
ISIN: US45408X3089
IGC Pharma, Inc
IGC
LISTED
XASE
IGC Pharma Expands CALMA Phase 2 Trial with Site at Lynn Health Science Institute in Oklahoma City
News Preview
POTOMAC, MD / ACCESS Newswire / August 25, 2025 / IGC Pharma, Inc. (NYSE American:IGC) today announced the expansion of its ongoing Phase 2 clinical trial evaluating IGC-AD1, an investigational drug candidate for treating agitation in patients with Alzheimer's disease. The Company has added a clinical site at the Lynn Health Science Institute (LHSI...
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
ISIN: KYG0146B1032
Akeso, Inc.
9926
LISTED
HKSE
Akeso Reports Phase 3 Trials Show Positive Results: Gumokimab (IL-17) for Ankylosing Spondylitis and Manfidokimab (IL-4Rα) for Atopic Dermatitis Achieve Primary Endpoints
News Preview
HONG KONG, Aug. 25, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) ("Akeso" or "the Company") today announced positive results from its Phase 3 clinical trial of gumokimab (AK111), a novel, fully human anti-IL-17A monoclonal antibody, for the treatment of active ankylosing spondylitis (AS). The study successfully met all primary efficacy endpoints, in...
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
ISIN: US09062X1037
Biogen Inc
BIIB
LISTED
NASDAQ
Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI® (lecanemab)
News Preview
TOKYO and CAMBRIDGE, Mass., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today that the anti-amyloid beta (Aβ) monoclonal antibody “LEQEMBI®” has been launched i...
Themefolio
Profiler
Peergroup
© ACCESSWIRE
25.08.2025
ISIN: US74366E1029
Protagonist Therapeutics Inc
PTGX
LISTED
NASDAQ
Rusfertide Receives Breakthrough Therapy Designation for Treatment of Erythrocytosis in Patients with Polycythemia Vera
News Preview
Breakthrough Therapy designation complements Rusfertide's Orphan Drug and Fast Track designations, which together confer multiple benefits to the development programU.S. New Drug Application filing for Rusfertide in polycythemia vera on track for Q4 NEWARK, CA / ACCESS Newswire / August 25, 2025 / Protagonist Therapeutics, Inc. ("Protagonist&q...
Themefolio
Profiler
Peergroup
© EQS Newswire
25.08.2025
ISIN: CH0039821084
Metall Zug AG
METN
LISTED
SIX
Metall Zug – Ergebnis für das erste Halbjahr 2025
News Preview
Ad hoc-Mitteilung gemäss Art. 53 Kotierungsreglement
Zug, 25. August 2025 – Metall Zug (SIX: METN) veröffentlicht das Ergebnis für das erste Halbjahr 2025
Haag-Streit führt drei neue, innovative Produkte auf dem Markt ein – im Kerngeschäft Spaltlampen wird eine Weltneuheit lanciert
CEO-Wechsel bei Haag-Streit: Thomas Lenzen übernimmt die CEO-Rolle......
Themefolio
Profiler
Peergroup
© EQS Newswire
25.08.2025
ISIN: CH0039821084
Metall Zug AG
METN
LISTED
SIX
Metall Zug – result for the first half of 2025
News Preview
Ad hoc announcement pursuant to Art. 53 Listing Rules of SIX Swiss Exchange
Zug, August 25, 2025 – Metall Zug (SIX: METN) announces result for the first half of 2025
Haag-Streit launches three new, innovative products – a world novelty is being introduced in its core core business of slit lamps
Change of CEO at Haag-Streit: Thomas Lenzen will tak......
Themefolio
Profiler
Peergroup
© Globe Newswire
25.08.2025
ISIN: FR0012127173
OSE Immunotherapeutics SA
OSE
LISTED
EURONEXT
OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General Meeting
News Preview
OSE Immunotherapeutics Proposes Governance Evolution and Reaffirms Strategic Priorities ahead of Annual General MeetingNew Board Structure Reflects Balanced and Proportionate Shareholder Representation New Governance to Drive Strategic Roadmaps for Tedopi® and Lusvertikimab...
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
ISIN: KYG4403H1002
Hbm Holdings Limited
2142
LISTED
HKSE
Harbour BioMed Appoints Yajie Li as Chief Medical Officer
News Preview
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Aug. 24, 2025 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company focused on the discovery and development of novel antibody therapeutics in immunology and oncology, today announced the appointment of Yajie Li as Chief Medical Officer (CMO). Ms. Li...
Themefolio
Profiler
Peergroup
© PR Newswire
25.08.2025
ISIN: KYG4818G1010
Innovent Biologics Inc
1801
LISTED
HKSE
Innovent Biologics Announces U.S. FDA IND Approval for the First Global MRCT Phase 3 Study (MarsLight-11) of IBI363 (PD-1/IL-2α-bias) in Squamous Non-Small Cell Lung Cancer
News Preview
SAN FRANCISCO and SUZHOU, China, Aug. 24, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company committed to developing, manufacturing and commercializing high-quality medicines in oncology, cardiovascular and metabolic diseases, autoimmune, ophthalmology and other major therapeutic area...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
